Breast cancer - bevacizumab (in combination with a taxane): consultee and commentator comments on the ACD
Breast cancer - bevacizumab (in combination with a taxane): Roche Products
Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer
Breast cancer - bevacizumab (in combination with a taxane): Department of Health
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Pathologists
Breast cancer - bevacizumab (in combination with a taxane): Kensington and Chelsea PCT
Breast cancer - bevacizumab (in combination with a taxane): Bristol Myers - Squib Pharmaceuticals
Breast cancer - bevacizumab (in combination with a taxane): York ERG response to the Appraisal Consultation Document
Breast cancer - bevacizumab (in combination with a taxane): Roche Products - new submission
Breast cancer - bevacizumab (in combination with a taxane): York ERG addendum
This page was last updated: 29 December 2014